Compare AU
Compare MOAT vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Morningstar US 'Wide Moat' (MOAT) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
MOAT | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 522 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,422.99 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Key Summary
MOAT | DRUG | |
|---|---|---|
Strategy | The key objective of the MOAT fund is to track the performance of the Morningstar Wide Moat Focus NR AUD Index before considering any fees, expenses, and taxes. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Salesforce Inc (3.26 %) Bristol-Myers Squibb Co (2.95 %) Autodesk Inc (2.90 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (23.89 %) Health Care (21.03 %) Information Technology (20.60 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (98.74 %) Netherlands (1.26 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.49 % | 0.57 % |
Key Summary
MOAT | DRUG | |
|---|---|---|
Issuer | VanEck | BetaShares |
Tracking index | Morningstar Wide Moat Focus Index - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.49 % | 0.57 % |
Price | $134.03 | $8.12 |
Size | $1.007 billion | $182.401 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 3.81 % | 1.90 % |
Market | ASX | ASX |
First listed date | 26/06/2015 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
MOAT | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 522 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,422.99 | $1,875.72 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
MOAT | DRUG | |
|---|---|---|
Pros |
| |
Cons |
|
MOAT | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |